Stress Hydrocortisone In Pediatric Septic Shock
Key facts
- Who runs it
- Jerry Zimmerman
- Where
- Boston, Chicago, Cincinnati, Hershey, Livingston, Los Angeles, Louisville, Madison, Memphis, Oakland, Oklahoma City, Orange, Peoria, Salt Lake City, San Francisco, Seattle, Tucson, and Wilmington, United StatesSee the 18 sitesAlso in 9 other countries, 26 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 500 people, planned
- Started
- 11 Mar 2019
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Hydrocortisone, sodium succinate
- Normal saline
- Record updated
- 30 October 2025
Who can take part
- Age
- 1 month to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- A child receiving treatment in a pediatric intensive care unit is eligible for recruitment into SHIPSS if she/he meets all of the following inclusion criteria:
- Age is at least 1 month (with corrected gestational age ≥42 weeks), but less than 17 years and 8 months of age
- A documented focus of infection or a strong suspicion of infection at PICU admission, or for patients who develop septic shock during PICU stay, at the onset of the septic shock event
- Surveillance cultures (e.g. blood, urine, cerebral spinal fluid, wound) and/or other microbial diagnostic tests have been obtained
- One or more antimicrobials have been prescribed
- Core temperature >38.5 C or <36.0 C or leukocytosis or leukopenia (as defined by the local laboratory) or a left-shifted leukocyte differential (>10% immature granulocyte forms) or a neutrophil count of <0.5 x 109 cells per litre documented at least once within the 24 hours preceding screening
- Treatment with a continuous infusion of vasoactive-inotropic agent(s) to maintain mean or systolic arterial blood pressure above the age-appropriate target set by the treating clinician
- Administration of two or more vasoactive-inotropic agents at any dose or epinephrine or norepinephrine infusion(s) alone at greater than or equal to 0.10 mcg/kg/min for >1 hour
Who cannot take part
- A child receiving treatment in a pediatric intensive care unit for sepsis is ineligible for enrollment into SHIPSS if she/he meets any of the following exclusion criteria:
- Attending physician expects to prescribe systemic corticosteroids for an indication other than septic shock
- Patient has received any doses of systemic corticosteroids during treatment for sepsis
- Known or suspected hypothalamic, pituitary or adrenal disease (including patient has received acute or chronic corticosteroid administration and the physician intends to provide corticosteroid for suspected adrenal suppression)
- Previous enrollment in the SHIPSS study
- Patient admitted directly to the PICU with a thermal burn who has been in the PICU for <72 hours prior to meeting SHIPSS inclusion criteria
- Patient in whom steroids are contraindicated at time of screening (e.g. treatment for systemic fungal infection, cerebral malaria, strongyloides)
- All inclusion criteria have been present for > 12 hours
- Enrolled concurrently in a competing interventional clinical trial (formal assessment to be conducted by SHIPSS Core Committee for each potential competing trial)
- Etomidate or ketoconazole treatment within past 48 hours
- Attending physician, PICU care team, or legally recognized guardians not committed to full treatment and resuscitation at the time of screening
- Patient documented to be pregnant
- (U.S. sites only) Patient in the custody of US protective services
- Patient being evaluated for brain death
- Vasoactive-inotropic agents prescribed solely for an indication other than septic shock
- Confirmed dengue fever
Where in United States
Also in 9 other countries, 26 sites
- Boston Children's HospitalBoston, United StatesContact: Michael Agus, MDTaking people
- University of Chicago Comer Children's HospitalChicago, United StatesContact: Grace Chong, MDTaking people
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Ranjit R Chima, MDTaking people
- Penn State Milton S. Hershey Children's HospitalHershey, United StatesContact: Robert Kavanagh, MDTaking people
- Saint Barnabas Medical CenterLivingston, United StatesContact: Shira J Gertz, MDTaking people
- Children's Hospital of Los AngelesLos Angeles, United StatesContact: Christopher Newth, MDTaking people
- University of Louisville, Norton Children's HospitalLouisville, United StatesContact: John Berkenbosch, MDTaking people
- University of Wisconsin Health/American Family Children's HospitalMadison, United StatesContact: Pelin Cengiz, MDTaking people
- Le Bonheur Children's HospitalMemphis, United StatesContact: Samir Shah, MDNot yet recruiting
- UCSF Benioff Children's Hospital OaklandOakland, United StatesContact: Natalie Cvijanovich, MDTaking people
- The Children's Hospital at Oklahoma University Medical CenterOklahoma City, United StatesContact: Christine Allen, MDTaking people
- Children's Hospital of Orange CountyOrange, United StatesContact: Adam Schwarz, MDTaking people
- The University of Illinois at Chicago/OSF Children's Hospital of IllinoisPeoria, United StatesContact: Sandeep Tripath, MDTaking people
- Primary Children's HospitalSalt Lake City, United StatesContact: Jennifer Workman, MDTaking people
- UCSF Benioff Children's Hospital - San FranciscoSan Francisco, United StatesContact: Patrick McQuillen, MDTaking people
- Seattle Children's HospitalSeattle, United StatesContact: Jerry J Zimmerman, MD, PhDTaking people
- University of Arizona Medical CentreTucson, United StatesContact: Katri Typpo, MDTaking people
- Nemours Children's HealthWilmington, United StatesContact: Catherine Madurski, MDTaking people
About the trial
What the trial wants to find out
SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock.
Read full original descriptionShow less
It is hypothesized that adjunctive hydrocortisone will significantly reduce the incidence of new and progressive organ dysfunction (primary outcome) and proportion of children with poor outcomes, defined as death or severely impaired health-related quality of life (HRQL) (secondary outcome), as assessed at 28 days following study enrollment (randomization).
The 2 groups in the trial
- TreatmentExisting treatment, for comparison
Approximately half of the subjects randomized into SHIPSS will be randomized into the Treatment Group and will receive hydrocortisone sodium succinate according to a predetermined dosing schedule.
Treatment: Hydrocortisone, sodium succinate
- PlaceboPlacebo, for comparison
Approximately half of the subjects randomized into SHIPSS will be randomized into the Placebo Group and will receive equivalent study drug volumes of normal saline.
Treatment: Normal saline
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Stress Hydrocortisone in Pediatric Septic Shock: Protocol for a Pragmatic, Multicenter, International, Randomized, Double-Blinded, Placebo-Controlled Interventional Trial.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2026
- Record updated
- 30 October 2025